MiR‑495 suppresses cell proliferation by directly targeting HMGA2 in lung cancer

Sun,Jiangtao; Qiao,Yanping; Song,Tao; Wang,Haiwen

doi:10.3892/mmr.2018.9773

MiR‑495 suppresses cell proliferation by directly targeting HMGA2 in lung cancer

Authors:
- Jiangtao Sun
- Yanping Qiao
- Tao Song
- Haiwen Wang
View Affiliations

Affiliations: Department of Oncology, Weihai Central Hospital, Weihai, Shandong 264400, P.R. China, Department of Hematology, Weihai Central Hospital, Weihai, Shandong 264400, P.R. China, Department of Endocrinology, Weihai Central Hospital, Weihai, Shandong 264400, P.R. China, Department of Cardio‑Thoracic Surgery, Weihai Central Hospital, Weihai, Shandong 264400, P.R. China
Published online on: December 17, 2018 https://doi.org/10.3892/mmr.2018.9773
Pages: 1463-1470
Copyright: © Sun et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the expression of microRNA‑495 (miR‑495) in non‑small cell lung cancer (NSCLC) tissues and cells, as well as its function on the proliferation of lung cancer cells. The expression of miR‑495 in 122 pairs of NSCLC tissues and matched paracarcinoma tissues, as well as in human lung cancer cell lines (A549, H460, H1650, H520 and SK‑MES‑1) and the normal human pulmonary bronchial epithelial cell line 16HBE was determined using reverse transcription quantitative polymerase chain reaction (RT‑qPCR). As predicted by bioinformatics analysis, high mobility group A2 (HMGA2) may be a potential target gene of miR‑495. In addition, the regulatory function of miR‑495 on its target gene HMGA2 was evaluated using a dual‑luciferase reporter assay, RT‑qPCR and western blotting. Furthermore, the effect of miR‑495 on the proliferation of A549 lung cancer cells was investigated using a Cell Counting Kit‑8 (CCK‑8) assay. The results demonstrated that the expression of miR‑495 in NSCLC tissues and cells was significantly downregulated compared with the control. In addition, downregulated expression of miR‑495 was associated with tumor differentiation, lymph node metastasis and tumor, node and metastasis staging. Additionally, a dual‑luciferase reporter assay revealed that miR‑495 could directly associated with the 3'‑untranslated region of HMGA2. Upregulated expression of miR‑495 significantly downregulated the mRNA and protein expression levels of HMGA2 in A549 cells. Furthermore, the results of CCK‑8 assay revealed that upregulated expression of miR‑495 significantly suppressed the proliferation of A549 cells; HMGA2 overexpression reversed this inhibition. In summary, the findings of the present study demonstrated that miR‑495 was downregulated in NSCLC tissues and cells. In addition, miR‑495 suppressed the proliferation of lung cancer cells by directly targeting HMGA2.

View Figures

View References

1	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
2	Ridge CA, Mcerlean AM and Ginsberg MS: Epidemiology of lung cancer. Semin Intervent Radiol. 30:93–98. 2013. View Article : Google Scholar : PubMed/NCBI
3	Wakelee H, Kelly K and Edelman MJ: 50 Years of progress in the systemic therapy of non-small cell lung cancer. Am Soc Clin Oncol Educ Book. 177–189. 2014. View Article : Google Scholar : PubMed/NCBI
4	Zhan P, Qian Q and Yu LK: Prognostic value of COX-2 expression in patients with non-small cell lung cancer: A systematic review and meta-analysis. J Thorac Dis. 5:40–47. 2013.PubMed/NCBI
5	Sheng M, Zhao Y, Wang F, Li S, Wang X, Shou T, Luo Y and Tang W: Targeted drugs for unselected patients with advanced non-small-cell lung cancer: A network meta-analysis. J Thorac Dis. 8:98–115. 2016.PubMed/NCBI
6	Acunzo M and Croce CM: MicroRNA in cancer and cachexia-a mini-review. J Infect Dis. 212 Suppl 1:S74–S77. 2015. View Article : Google Scholar : PubMed/NCBI
7	Farazi TA, Spitzer JI, Morozov P and Tuschl T: miRNAs in human cancer. J Pathol. 223:102–115. 2011. View Article : Google Scholar : PubMed/NCBI
8	Sorel O and Dewals BG: MicroRNAs in large herpesvirus DNA genomes: Recent advances. Biomol Concepts. 7:229–239. 2016. View Article : Google Scholar : PubMed/NCBI
9	Li Z, Zhang G, Li D, Jie Z, Chen H, Xiong J, Liu Y, Cao Y, Jiang M, Le Z and Tan S: Methylation-associated silencing of miR-495 inhibit the migration and invasion of human gastric cancer cells by directly targeting PRL-3. Biochem Biophys Res Commun. 456:344–350. 2015. View Article : Google Scholar : PubMed/NCBI
10	Mao Y, Li L, Liu J, Wang L and Zhou Y: MiR-495 inhibits esophageal squamous cell carcinoma progression by targeting Akt1. Oncotarget. 7:51223–51236. 2016. View Article : Google Scholar : PubMed/NCBI
11	Yan L, Yao J and Qiu J: miRNA-495 suppresses proliferation and migration of colorectal cancer cells by targeting FAM83D. Biomed Pharmacother. 96:974–981. 2017. View Article : Google Scholar : PubMed/NCBI
12	Lu Y, Liu WG, Lu JH, Liu ZJ, Li HB, Liu GJ, She HY, Li GY and Shi XH: LncRNA UCA1 promotes renal cell carcinoma proliferation through epigenetically repressing p21 expression and negatively regulating miR-495. Tumour Biol. 39:10104283177016322017. View Article : Google Scholar : PubMed/NCBI
13	Tan M, Mu X, Liu Z, Tao L, Wang J, Ge J and Qiu J: microRNA-495 promotes bladder cancer cell growth and invasion by targeting phosphatase and tensin homolog. Biochem Biophys Res Commun. 483:867–873. 2017. View Article : Google Scholar : PubMed/NCBI
14	Wang J, Wu N, Zheng Q, Feng Y, Yan S, Lv C, Li S, Wang Y and Yang Y: Evaluation of the 7th edition of the TNM classification for lung cancer at a single institution. J Cancer Res Clin Oncol. 140:1189–1195. 2014. View Article : Google Scholar : PubMed/NCBI
15	Livak KJ and Schimittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
16	Mehta A, Dobersch S, Romero-Olmedo AJ and Barreto G: Epigenetics in lung cancer diagnosis and therapy. Cancer Metastasis Rev. 34:229–241. 2015. View Article : Google Scholar : PubMed/NCBI
17	Hesse M and Arenz C: MicroRNA maturation and human disease. Methods Mol Biol 1095. 11–25. 2014. View Article : Google Scholar
18	Salido-Guadarrama I, Romero-Cordoba S, Peralta-Zaragoza O, Hidalgo-Miranda A and Rodríguez-Dorantes M: MicroRNAs transported by exosomes in body fluids as mediators of intercelluar communication in cancer. Onco Targets Ther. 7:1327–1338. 2014.PubMed/NCBI
19	Wang Z, Yao H, Lin S, Zhu X, Shen Z, Lu G, Poon WS, Xie D, Lin MC and Kung HF: Transcriptional and epigenetic regulation of human microRNAs. Cancer Lett. 331:1–10. 2013. View Article : Google Scholar : PubMed/NCBI
20	Li X, Song Y, Liu D, Zhao J, Xu J, Ren J, Hu Y, Wang Z, Hou Y and Zhao G: MiR-495 promotes senescence of mesenchymal stem cells by targeting Bmi-1. Cell Physiol Biochem. 42:780–796. 2017. View Article : Google Scholar : PubMed/NCBI
21	Zhang X, Yang Y and Feng Z: Suppression of microRNA-495 alleviates high-glucose-induced retinal ganglion cell apoptosis by regulating Notch/PTEN/Akt signaling. Biomed Pharmacother. 106:923–929. 2018. View Article : Google Scholar : PubMed/NCBI
22	Bai Z, Wang J, Wang T, Li Y, Zhao X, Wu G, Yang Y, Deng W and Zhang Z: The MiR-495/Annexin A3/P53 axis inhibits the invasion and EMT of colorectal cancer cells. Cell Physiol Biochem. 44:1882–1895. 2017. View Article : Google Scholar : PubMed/NCBI
23	Yang H, Cho ME, Li TW, Peng H, Ko KS, Mato JM and Lu SC: MicroRNAs regulate methionine adenosyltransferase 1A expression in hepatocellular carcinoma. J Clin Invest. 123:285–298. 2013. View Article : Google Scholar : PubMed/NCBI
24	Hwang-Verslues WW, Chang PH, Wei PC, Yang CY, Huang CK, Kuo WH, Shew JY, Chang KJ, Lee EY and Lee WH: miR-495 is upregulated by E12/E47 in breast cancer stem cells, and promotes oncogenesis and hypoxia resistance via downregulation of E-cadherin and REDD1. Oncogene. 30:2463–2474. 2011. View Article : Google Scholar : PubMed/NCBI
25	Liu B, Li J and Cairns MJ: Identifying miRNAs, targets and functions. Brief Bioinform. 15:1–19. 2014. View Article : Google Scholar : PubMed/NCBI
26	Chu H, Chen X, Wang H, Du Y, Wang Y, Zang W, Li P, Li J, Chang J, Zhao G and Zhang G: MiR-495 regulates proliferation and migration in NSCLC by targeting MTA3. Tumour Biol. 35:3487–3494. 2014. View Article : Google Scholar : PubMed/NCBI
27	Yang F, Zhao L, Mei D, Jiang L, Geng C, Li Q, Yao X, Liu Y, Kong Y and Cao J: HMGA2 plays an important role in Cr (VI)-induced autophagy. Int J Cancer. 141:986–997. 2017. View Article : Google Scholar : PubMed/NCBI
28	Busch B, Bley N, Müller S, Glaß M, Misiak D, Lederer M, Vetter M, Strauß HG, Thomssen C and Hüttelmaier S: The oncogenic triangle of HMGA2, LIN28B and IGF2BP1 antagonizes tumor-suppressive actions of the let-7 family. Nucleic Acids Res. 44:3845–3864. 2016. View Article : Google Scholar : PubMed/NCBI
29	Jin L, Lloyd RV, Henry MR, Erickson LA, Sebo TJ, Rumilla KM and Zhang J: The diagnostic utility of combination of HMGA2 and IMP3 qRT-PCR testing in thyroid neoplasms. Appl Immunohistochem Mol Morphol. 23:36–43. 2015. View Article : Google Scholar : PubMed/NCBI
30	Yang J, Zhang Q, Dong JQ, Chang XH and He XJ: Overexpression of high mobility group A2 and its correlation with microRNA let-7 family in serous ovarian cancers. Beijing Da Xue Xue Bao Yi Xue Ban. 44:749–754. 2012.(In Chinese). PubMed/NCBI
31	Zhu C, Li J, Cheng G, Zhou H, Tao L, Cai H, Li P, Cao Q, Ju X, Meng X, et al: miR-154 inhibits EMT by targeting HMGA2 in prostate cancer cells. Mol Cell Biochem. 379:69–75. 2013. View Article : Google Scholar : PubMed/NCBI
32	Zou Q, Xiong L, Yang Z, Lv F, Yang L and Miao X: Expression levels of HMGA2 and CD9 and its clinicopathological significances in the benign and malignant lesions of the gallbladder. World J Surg Oncol. 10:922012. View Article : Google Scholar : PubMed/NCBI
33	Liu Q, Lv GD, Qin X, Gen YH, Zheng ST, Liu T and Lu XM: Role of microRNA let-7 and effect to HMGA2 in esophageal squamous cell carcinoma. Mol Biol Rep. 39:1239–1246. 2012. View Article : Google Scholar : PubMed/NCBI
34	Ding X, Wang Y, Ma X, Guo H, Yan X, Chi Q, Li J, Hou Y and Wang C: Expression of HMGA2 in bladder cancer and its association with epithelial-to-mesenchymal transition. Cell Prolif. 47:146–151. 2014. View Article : Google Scholar : PubMed/NCBI
35	Meyer B, Loeschke S, Schultze A, Weigel T, Sandkamp M, Goldmann T, Vollmer E and Bullerdiek J: HMGA2 overexpression in non-small cell lung cancer. Mol Carcinog. 46:503–511. 2007. View Article : Google Scholar : PubMed/NCBI
36	Kong D, Su G, Zha L, Zhang H, Xiang J, Xu W, Tang Y and Wang Z: Coexpression of HMGA2 and Oct4 predicts an unfavorable prognosis in human gastric cancer. Med Oncol. 31:1302014. View Article : Google Scholar : PubMed/NCBI
37	Fusco A and Fedele M: Roles of HMGA proteins in cancer. Nat Rev Cancer. 7:899–910. 2007. View Article : Google Scholar : PubMed/NCBI
38	Denechaud PD, Fajas L and Giralt A: E2F1, a novel regulator of metabolism. Front Endocrinol (Lausanne). 8:3112017. View Article : Google Scholar : PubMed/NCBI
39	Fedele M, Pierantoni GM, Visone R and Fusco A: E2F1 activation is responsible for pituitary adenomas induced by HMGA2 gene overexpression. Cell Div. 1:172006. View Article : Google Scholar : PubMed/NCBI
40	Loukil A, Cheung CT, Bendris N, Lemmers B, Peter M and Blanchard JM: Cyclin A2: At the crossroads of cell cycle and cell invasion. World J Biol Chem. 6:346–350. 2015. View Article : Google Scholar : PubMed/NCBI
41	Tessari MA, Gostissa M, Altamura S, Sgarra R, Rustighi A, Salvagno C, Caretti G, Imbriano C, Mantovani R, Del Sal G, et al: Transcriptional activation of the cyclin A gene by the architectural transcription factor HMGA2. Mol Cell Biol. 23:9104–9116. 2003. View Article : Google Scholar : PubMed/NCBI
42	D'Angelo D, Esposito F and Fusco A: Epigenetic mechanisms leading to overexpression of HMGA proteins in human pituitary adenomas. Front Med (Lausanne). 2:392015.PubMed/NCBI
43	Morishita A, Zaidi MR, Mitoro A, Sankarasharma D, Szabolcs M, Okada Y, D'Armiento J and Chada K: HMGA2 is a driver of tumor metastasis. Cancer Res. 73:4289–4299. 2013. View Article : Google Scholar : PubMed/NCBI
44	Di Cello F, Hillion J, Hristov A, Wood LJ, Mukherjee M, Schuldenfrei A, Kowalski J, Bhattacharya R, Ashfaq R and Resar LM: HMGA2 participates in transformation in human lung cancer. Mol Cancer Res. 6:743–750. 2008. View Article : Google Scholar : PubMed/NCBI